← ARROWHEAD PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $85.4m | $24.8m | $30.1m | $221.8m | $143.6m | $184.4m | — | — | — | — | |
| Assets, Current | $90.5m | $67.9m | $78.8m | $265.2m | $322.4m | $384.6m | $405.3m | $419.5m | $695.5m | $950.6m | |
| Property, Plant and Equipment, Net | $15.4m | $15.5m | $13.9m | $23.2m | $30.9m | $48.7m | $110.3m | $290.3m | $386.0m | $382.5m | |
| Intangible Assets, Net (Excluding Goodwill) | $22.2m | — | — | — | — | — | — | — | — | — | |
| Operating Lease, Right-of-Use Asset | — | — | — | — | $16.1m | $17.3m | $58.3m | $45.3m | $45.3m | $43.9m | |
| Other Assets, Noncurrent | $122k | $142k | $142k | $144k | $265k | $272k | $218k | $210k | $4.5m | $1.4m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $75k | $68k | $327k | $661k | $846k | $10.3m | $1.4m | $0 | $0 | $6.8m | |
| Accrued Liabilities, Current | $4.6m | $4.6m | $5.0m | $6.5m | $5.4m | $14.0m | $46.9m | $39.8m | $63.0m | $90.4m | |
| Assets | $128.2m | $104.0m | $111.6m | $349.8m | $522.5m | $710.1m | $691.9m | $765.6m | $1.1b | $1.4b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | — | $1.1m | $2.2m | $2.8m | $10.6m | $6.3m | $7.3m | |
| Accounts Payable, Current | $12.2m | $4.1m | $2.8m | $7.6m | $6.8m | $9.5m | $2.9m | $35.9m | $11.4m | $17.7m | |
| Operating Lease, Liability, Noncurrent | — | — | — | — | $20.0m | $23.3m | $78.8m | $104.6m | $111.0m | $104.1m | |
| Deferred Revenue, Current | $2.6m | $5.3m | $600 | $77.8m | $19.3m | $111.1m | $74.1m | $866k | $0 | $2.4m | |
| Deferred Revenue, Noncurrent | $2.5m | $5.3m | $600 | $77.8m | $19.3m | $111.1m | $74.1m | $866k | $0 | $2.4m | |
| Liabilities, Current | $25.6m | $18.7m | $12.4m | $97.1m | $40.7m | $146.5m | $138.8m | $105.5m | $103.2m | $195.5m | |
| Other Liabilities, Noncurrent | $200k | $200k | $200k | — | — | — | — | — | — | — | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | $16 | — | — | — | — | — | — | — | — | — | |
| Common Stock, Value, Issued | $162k | $167k | $181k | $188k | $195k | $197k | $198k | $200k | $217k | $231k | |
| Additional Paid in Capital | $493.8m | $514.0m | $582.9m | $664.1m | $965.4m | $1.1b | $1.2b | $1.3b | $1.8b | $2.1b | |
| Retained Earnings (Accumulated Deficit) | ($398.4m) | ($432.8m) | ($487.3m) | ($419.3m) | ($503.8m) | ($644.7m) | ($820.8m) | ($1.0b) | ($1.6b) | ($1.6b) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $7k | $33k | ($22k) | ($392k) | $18k | ($69k) | ($136k) | ($3.2m) | $4.8m | $6.4m | |
| Additional Paid in Capital, Common Stock | — | — | — | $664.1m | $965.4m | $1.1b | $1.2b | $1.3b | $1.8b | $2.1b | |
| Stockholders' Equity Attributable to Parent | $95.6m | $81.4m | $95.8m | $244.6m | $461.8m | — | $398.5m | $271.3m | $185.4m | $466.1m | |
| Stockholders' Equity Attributable to Noncontrolling Interest | ($555k) | ($555k) | ($555k) | ($555k) | — | — | $19.8m | $15.8m | $5.6m | $37.4m | |
| Liabilities and Equity | $128.2m | $104.0m | $111.6m | $349.8m | $522.5m | $710.1m | $691.9m | $765.6m | $1.1b | $1.4b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.